Key points are not available for this paper at this time.
Effects of epoetin alfa on transfusions, haemoglobin (Hb) and quality of life (QOL) were evaluated in a placebo‐controlled study of 145 patients with multiple myeloma and anaemia (Hb < 11 g/dl). During the 12‐week, double‐blind phase, patients received 150 IU/kg epoetin alfa or a matching volume of placebo subcutaneously three times weekly; the dose (or volume) was doubled at week 4 if Hb response was inadequate. Patients completing this phase could enter the subsequent optional 12‐week phase of open‐label epoetin alfa treatment. During double‐blind treatment, epoetin alfa significantly decreased the incidence of transfusion compared with placebo (28% vs. 47%, P = 0·017), regardless of patients' transfusion history, and increased mean Hb (1·8 g/dl vs. 0·0 g/dl, P < 0·001). Univariate analysis showed significant ( P ≤ 0·05) improvement in more QOL measures with epoetin alfa than with placebo; multivariate analysis discerned no between‐treatment differences. Significantly ( P = 0·038) more epoetin alfa vs. placebo patients had improved performance scores. At the end of the open‐label treatment phase, patients who had continued epoetin alfa maintained Hb status, and placebo patients who were switched to epoetin alfa had mean Hb increases of 2·4 g/dl. Adverse events were similar between treatment groups. Epoetin alfa proved effective and well tolerated for treating anaemia in patients with multiple myeloma.
Dammacco et al. (Sun,) studied this question.